Chimeric antigen receptors targeting CD127 and use thereof

A method for reducing tumor burden in a subject having a hematological tumor, treating and/or preventing a hematological tumor in a subject, and/or increasing or lengthening survival of a subject having a hematological tumor, comprising administering to the subject

• a) an effective amount of cells comprising an antigen-recognizing receptor,
• b) a pharmaceutical composition comprising an effective amount of cells comprising an antigen-recognizing receptor;
• or
• c) a nucleic acid composition comprising a polynucleotide encoding an antigen-recognizing receptor;
• wherein the antigen-recognizing receptor comprises a chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen-binding domain specifically binds CD127 comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are positioned from a N- to a C-terminus:
• VH-VL, and
• wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
• 6, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
• 7, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
• 8, and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
• 9, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
• 10, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
• 11.